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doi:10.1016/j.numecd.2012.03.001Abstract Background and aims: There are few prospective studies on fatty acid status in
relation to incident stroke, with inconsistent results. We assessed the associations of plasma
n-6 and n-3 PUFA in cholesteryl esters with the risk of total stroke and stroke subtypes in Dutch
adults.
Methods and results: We conducted a nested caseecontrol study using data from a population-
based cohort study in adults aged 20e65 years. Blood sampling and data collection took place
during 1993e1997 and subjects were followed for 8e13 years. We identified 179 incident cases
of stroke and 179 randomly selected controls, matched on age, gender, and enrollment date.
Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated per standard deviation
(SD) increase of PUFA in cholesteryl esters using multivariable conditional logistic regression.
Cases comprised 93 ischemic, 50 hemorrhagic, and 36 unspecified strokes. The n-6 PUFA lino-
leic acid and arachidonic acid contributedw55% andw6.5% respectively to total plasma fatty
acids, whereas the n-3 PUFA alpha-linolenic acid contributed w0.5% and eicosapentaenoic
acid plus docosahexaenoic acid (EPA-DHA) w1.3%. After adjustment for confounders, n-6
and n-3 PUFA were not associated with incident total stroke or stroke subtypes. The OR
(95% CI) for total stroke was 0.95 (0.74e1.23) per SD increase in linoleic acid and 1.02 (0.80e
1.30) per SD increase in arachidonic acid. ORs (95% CI) for total stroke were 0.94 (0.72e1.21)
for alpha-linolenic acid and 1.16 (0.94e1.45) for EPA-DHA.l; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MORGEN, Monitoring Project on Risk
s ratio; PUFA, polyunsaturated fatty acids; SD, standard deviation.
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of EPA-DHA in erythrocytes with ischemic stroke in men butWorldwide, stroke is the second largest cause of death and
a major cause of long-term disability [1,2]. Stroke was the
third leading cause of burden of disease expressed in
disability adjusted life years (DALY) in middle and high
income countries in 2004, leading to substantial health care
costs [1]. A healthy lifestyle and diet are of utmost impor-
tance for the primary prevention of cardiovascular diseases,
including stroke [3e5]. Polyunsaturated fatty acids (PUFA)
may influence the risk of stroke, but data on biomarkers of
PUFA intake in relation to stroke risk are lacking.
Linoleic acid, belonging to the n-6 PUFA family, is the
most abundant PUFA in the diet and it is mainly obtained
from vegetable oils, such as sunflower oil and soybean oil
[6]. It is an essential fatty acid that can be elongated to
arachidonic acid, which is also present in meat in small
quantities [7,8]. Alpha-linolenic acid is an essential fatty
acid of the n-3 PUFA family and is present in soybean,
canola, and flaxseed oil [6]. Alpha-linolenic acid can be
elongated to eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA). Because these conversions only take
place to a limited extent [9], EPA and DHA are mainly
derived from the diet, through fish consumption [6].
Biomarkers of dietary intake are widely used in epide-
miological studies [10,11]. They are considered to be
a more accurate measure of intake than dietary records or
questionnaire data, especially when the nutrient of interest
varies widely within foods and food groups and when food
composition tables are inaccurate for that specific nutrient
[12]. Furthermore, biomarkers are not dependent on
a person’s ability to recall dietary intakes. Fatty acids can
be measured as free fatty acids in serum (or plasma), as
components of circulating triglycerides, erythrocyte
membranes, platelets, phospholipids or cholesteryl esters,
or in adipose tissue from various sites [13]. Cholesteryl
esters are found in plasma lipoproteins and reflect dietary
intake of PUFA during the previous weeks [14,15]. Whole
serum, serum fractions, and erythrocytes also reflect
a relatively short-term intake (between days and months).
In long-term observational studies, adipose tissue is
considered the best choice to assess habitual fatty acid
intake, because it reflects the intake of fatty acids during
the previous months to years [10,15]. However, blood tissue
is most widely used in observational studies because of its
accessibility and the assumption that individuals do not
make drastic short-term diet changes [10].
There are only a few prospective studies on fatty acid
status in relation to incident stroke [16e18]. In a Japanese
[17], but not in an American [16] nested caseecontrol
study, total serum linoleic acid and arachidonic acid were
inversely associated with incident stroke. Alpha-linolenic
acid in serum cholesteryl esters and phospholipids was
inversely associated with stroke risk in the American [16],
but not in the Japanese study [17]. In Japan, however, both
fatty acid intake and stroke incidence are very different
compared to Western countries [17]. A Swedish nestednot in women, whereas EPA-DHA status was not associated
with total stroke in men or in women [18]. In the Japanese
and American studies, EPA and DHA were not related to
stroke risk.
We investigated the associations of n-6 and n-3 fatty
acids, measured in plasma cholesteryl esters with the risk
of total stroke and stroke subtypes in a nested casee
control study of Dutch adults.
Methods
Study population
We conducted a nested caseecontrol study in the Monitoring
Project on Risk Factors for Chronic Diseases (MORGEN) study,
a Dutch population-based cohort study. Blood samples and
information on lifestyle, and cardiovascular risk factorswere
collected at baseline (1993e1997) in 22,654 subjects aged
20e65 years [19,20]. The survey complied with the Decla-
ration of Helsinki and the protocol was approved by the
Medical Ethics Committees of TNO Prevention and Health,
Leiden. Written informed consent was obtained from each
participant. We excluded participants who did not provide
informed consent for vital status follow-up, participants
without dietary information, and participants with a history
of myocardial infarction or stroke at baseline, resulting in
21,335 participants.
Vital statuswas checked through linkagewith thenational
population register. Participants were followed for cause-
specific mortality, including fatal stroke, through linkage
with Statistics Netherlands. Information on nonfatal stroke
was obtained from the national hospital discharge register as
described in more detail elsewhere [21]. It has been shown
that on the national level data from the Dutch hospital
discharge register can be uniquelymatched to a person for at
least 88% of the hospital admissions [21]. Total stroke
included I60-66, ischemic stroke included I63, I65, and I66,
and hemorrhagic stroke included I60-I62 according to the
International Classification of Diseases (ICD-10, WHO). For
hospital admissions and for causes of death coded until
January 1, 1996, corresponding ICD-9 codes were used.
Participants were followed until incident stroke, death, date
of loss-to-follow-up (predominantly because of emigration)
or 1 January 2006, whichever came first.
All cases of incident stroke (n Z 200) that occurred
during 8e13 years (median: 10.5 years) of follow-up were
identified. For each case, one control was selected based
on incidence density sampling [22,23]. Controls were
selected from those persons under study who survived at
least as long as the index case. A person was eligible to
serve as a control for multiple cases at a given moment in
time and could serve both as control and case. Cases were
individually matched on age (þ/0.5y), gender, and
enrollment date (þ/0.5y). Plasma was available for 179
caseecontrol pairs. Five participants were selected as
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and as a case.
Measurement of plasma n-3 PUFA in plasma
cholesteryl esters
Participants donated non-fasting blood at baseline. EDTA-
plasma was stored at 80 C until analyzed in 2010. Fatty
acids were measured in plasma cholesteryl esters by gas
chromatography, as described previously [24]. In short, to
isolate cholesteryl esters, lipids from EDTA plasma were
dissolved and separated by solid phase extraction silica
columns (Chrompack, Middelburg, The Netherlands). The
fatty acids were identified by comparison with known
standards (Nu-chek prep, Inc. Elysian, MN, USA). Fatty acids
were expressed as mass percentages of total fatty acid
methyl esters (g/100 g). A quality control plasma pool was
analyzed in duplicate in each run. Coefficients of variation
of the controls (intra and inter assay combined) ranged
between 3 and 3.5%. Laboratory technicians were blinded
to the status of the samples. Cases and controls were
randomly distributed over the runs.
Data collection on risk factors
The baseline measurements were previously described in
detail by Verschuren et al. [25]. Body weight, height, and
blood pressure were measured at baseline by trained
research nurses. Hypertensionwas defined as a systolic blood
pressure140 mmHg, a diastolic blood pressure90 mmHg,
or the use of blood pressure lowering medication. Non-
fasting plasma was analyzed for total and high-density lipo-
protein (HDL) cholesterol, and hypercholesterolemia was
defined as plasma total cholesterol  6.5 mmol/l or the use
of cholesterol lowering medication. Self-administered
questionnaires were used to assess the prevalence of dia-
betes, history of myocardial infarction or stroke, medication
use, educational level, and cigarette smoking. Alcohol
intake (based on a food frequency questionnaire [26,27])was
calculated in glasses/d andwas categorized as no intake, low
to moderate intake (men  2 and women  1 glasses/d), or
high intake (men > 2 and women > 1 glasses/d).
Statistical analysis
In descriptive analyses, we compared the prevalence of risk
factors and mean levels (SD) of plasma fatty acids
between cases and controls. The significance of differences
in crude means or frequencies of risk factors were assessed
by paired t-test for continuous variables and Wilcoxon
signed-rank test for categorical variables. Correlations
between the different types of fatty acids in plasma were
assessed with the Spearman rank correlation test.
We used conditional logistic regression models to
calculate odds ratios (OR) with 95% confidence intervals
(95% CI) for the association of plasma levels of linoleic
acid, arachidonic acid, alpha-linolenic acid, and EPA-DHA
with incidence of stroke. The analyses were repeated for
stroke subtypes, i.e. ischemic stroke and hemorrhagic
stroke. ORs and 95% CI for stroke were calculated per SD
increase in the plasma fatty acids, based on thedistribution of controls. In model 1, we adjusted for the
matching factors age, gender, and enrollment date. In
model 2, we additionally adjusted for current cigarette
smoking (yes/no), body mass index (kg/m2), alcohol intake
(none, low to moderate or high), high educational level
(completed higher vocational training or university), pres-
ence of diabetes mellitus (yes/no), hypertension (yes/no),
hypercholesterolemia (yes/no). Two-sided p-values 0.05
were considered statistically significant. All statistical
analyses were performed with Statistical Analysis Software
(SAS), version 9.2.
Results
Cases comprised 93 ischemic strokes, 50 hemorrhagic
strokes, and 36 unspecified strokes. Due to matching, case
and control participants had a similar mean age of around
50 years and 53% of both cases and controls were male.
Cases smoked more, were less educated, had higher
blood pressures, and more often had hypercholesterol-
emia or diabetes mellitus (Table 1). Plasma linoleic acid
was inversely correlated with plasma arachidonic acid
(r Z 0.27). Alpha-linolenic acid was positively corre-
lated with EPA-DHA (r Z 0.29). Alpha-linolenic acid
was inversely correlated with linoleic acid (0.19) (all
p < 0.001).
Table 2 shows fatty acid levels for stroke cases and
matched controls. The n-6 PUFA linoleic acid and arach-
idonic acid contributed w55% and w6.5% respectively to
total fatty acids in cholesteryl esters. N-3 PUFA levels
alpha-linolenic acid contributed w0.5% and EPA-DHA
w1.3%, with an EPA to DHA ratio of w3:2. Fatty acid
levels did not differ between cases and controls, except for
EPA-DHA which was higher in cases of total stroke
(p Z 0.07) and cases of ischemic stroke (p Z 0.02). Of
note, the standard deviation for EPA-DHA in cases was
relatively large compared to controls.
In Table 3, ORs (95% CI) of incident total stroke and
stroke subtypes are presented per SD increase (based on
the distribution of controls) in the n-6 and n-3 fatty acids.
After adjustment for confounders, n-6 PUFA were not
associated with incident stroke. The ORs (95% CI) for total
stroke were 0.95 (0.74e1.23) per SD increase of linoleic
acid and 1.02 (0.80e1.30) per SD increase of arachidonic
acid. N-3 fatty acids were also not related to total stroke
risk, with ORs (95% CI) for total stroke of 0.94 (0.72e1.21)
for alpha-linolenic acid and 1.16 (0.94e1.45) for EPA plus
DHA. In addition, no significant associations were observed
between n-6 and n-3 fatty acid status and incidence of
ischemic or hemorrhagic stroke.
Discussion
The present nested caseecontrol study in an adult Dutch
population, showed no association between cholesteryl
ester plasma levels of n-6 fatty acids (linoleic acid and
arachidonic acid) or n-3 (alpha-linolenic acid and EPA-DHA)
fatty acids and incidence of total stroke or stroke subtypes.
Several methodological issues should be addressed. The
nested caseecontrol design is considered an efficient
alternative to a full-cohort analysis [28]. In addition,
Table 1 Characteristics of 179 Dutch stroke cases and 179 matched controls.a,b
Cases (n Z 179) Controls (n Z 179) P-valuec
Male gender, % 53 53 e
Age, y 50.1  9.5 50.0  9.5 e
Body mass index, kg/m2 25.8  4.1 25.9  4.3 0.74
Smoking, %
Never 21 40 e
Former 30 35 e
Current 49 26 <0.0001
Alcohol consumption, %
No intake 20 11 e
Low to moderate 49 63 e
High 31 26 0.51
High educational level, %d 12 22 0.01
Diabetes mellitus, % 5.6 0.6 0.001
Systolic blood pressure, mm Hg 132.1  20.2 126.1  16.1 0.002
Diastolic blood pressure, mm Hg 82.9  12.0 80.9  11.3 0.11
Hypertension, % 42.1 30.7 0.02
Plasma total cholesterol, mmol/le 5.7  1.1 5.6  1.1 0.29
Plasma HDL-cholesterol, mmol/le 1.3  0.4 1.3  0.3 0.23
Hypercholesterolemia, % 28.5 20.1 0.04
a Values are means  SD, unless indicated otherwise.
b Controls were matched on age, gender, and enrollment date.
c Paired t-test for linear values Wilcoxon signed-rank test for proportions.
d Completed higher vocational training or university.
e Non-fasting.
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to reduce the likelihood of biased results [22,23]. Choles-
teryl ester levels of linoleic acid, alpha-linolenic acid, EPA,
and DHA are considered a reliable proxy of dietary intake of
n-3 PUFA during the previous weeks [14,15], because they
are not (alpha-linolenic acid and linoleic acid) or hardlyTable 2 Fatty acid proportions in plasma cholesteryl esters in
Fatty acids (g/100 g)c
Total stroke
Linoleic acid C18:2n  6
Arachidonic acid C20:4n  6
Alpha-linolenic acid C18:3n  3
EPAeDHA C20:5n  3 þ C22:6n  3
Ischemic stroke
Linoleic acid C18:2n  6
Arachidonic acid C20:4n  6
Alpha-linolenic acid C18:3n  3
EPAeDHA C20:5n  3 þ C22:6n  3
Hemorrhagic stroke
Linoleic acid C18:2n  6
Arachidonic acid C20:4n  6
Alpha-linolenic acid C18:3n  3
EPAeDHA C20:5n  3 þ C22:6n  3
a Fatty acid levels are expressed as mass percentages of total fatty
b Controls were matched on age, gender, and enrollment date.
c Fatty acid levels are expressed as means  SD.
d Paired t-test.
e Paired t-test was performed on the log transformed values of EPA(EPA and DHA) endogenously synthesized [9]. In Western
diets, arachidonic levels are more influenced by synthesis
from linoleic acid than by dietary intake [7].
The blood samples had been stored for 12e17 years
which may have affected the quality of plasma fatty acids.
However, storage up to 10 years at 80 C did not179 Dutch stroke cases and 179 matched controls.a,b
Cases Controls P-valued
N Z 179 NZ179
54.4  5.8 55.2  5.3 0.17
6.6  1.7 6.5  1.6 0.70
0.53  0.14 0.52  0.15 0.80
1.43  1.04 1.23  0.56 0.07e
N Z 93 N Z 93
54.2  5.7 55.4  5.5 0.15
6.7  1.7 6.4  1.5 0.15
0.53  0.13 0.52  0.14 0.41
1.57  1.25 1.25  0.60 0.02e
N Z 50 N Z 50
53.5  6.1 55.2  4.6 0.14
6.4  1.7 6.6  1.7 0.49
0.54  0.14 0.54  0.16 0.86
1.29  0.78 1.12  0.40 0.45e
acids.
-DHA
Table 3 Associations between plasma fatty acids and
incident stroke, matched by age, gender, and enrollment
datea
Model 1b Model 2c
OR (95% CI) OR (95% CI)
Total stroke N Z 179 N Z 179
Linoleic acid 0.87 (0.71e1.07) 0.95 (0.74e1.24)
Arachidonic acid 1.04 (0.84e1.29) 1.02 (0.80e1.30)
Alpha-linolenic acid 1.03 (0.82e1.29) 0.94 (0.72e1.21)
EPA-DHA 1.23 (1.02e1.50) 1.16 (0.94e1.45)
Ischemic stroke N Z 93 N Z 93
Linoleic acid 0.79 (0.57e1.09) 0.81 (0.54e1.24)
Arachidonic acid 1.22 (0.93e1.62) 1.21 (0.88e1.67)
Alpha-linolenic acid 1.14 (0.84e1.56) 1.02 (0.71e1.46)
EPA-DHA 1.34 (1.01e1.78) 1.33 (0.96e1.84)
Hemorrhagic stroke N Z 50 N Z 50
Linoleic acid 0.74 (0.49e1.11) 1.01 (0.56e1.83)
Arachidonic acid 0.87 (0.59e1.29) 0.84 (0.51e1.39)
Alpha-linolenic acid 0.96 (0.62e1.49) 0.73 (0.40e1.32)
EPA-DHA 1.23 (0.90e1.68) 1.08 (0.75e1.57)
EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid.
a Values are odds ratios (95% CI) per standard deviation
increase, based on conditional logistic models.
b Crude model, matched for age, gender, and enrollment
date.
c Additional adjustment for smoking, BMI, education level,
alcohol intake, diabetes, hypertension, hypercholesterolemia.
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profiles in a recent validation study [29]. In addition, the
number of detected fatty acids (15e20) and the percentage
of unknown fractions (rule of thumb <5 g/100 g) were as
expected. Furthermore, potential measurement error will
have been random because the plasma samples of cases
and controls were identically handled and analyzed in
random order, and lab technicians were blinded for disease
outcome.
Epidemiological studies of n-6 and n-3 fatty acid status
and stroke are scarce. In a nested caseecontrol study in 192
American middle-aged men at high risk for cardiovascular
diseases in the MRFIT study [16], the n-6 PUFA linoleic acid
or arachidonic acid were not related to stroke risk. This is in
line with the results of the present study. In our study, the
n-3 PUFA alpha-linolenic acid status was also not associated
with incident total stroke or ischemic stroke. In this respect
our results differed from those of the MRFIT study, which
had a similar distribution of alpha-linolenic acid in serum
cholesteryl esters, but a shorter follow-up time of 7 years.
In the MRFIT study, a 1-SD higher alpha-linolenic acid level
(0.13 g/100 g) was associated with a 37% lower risk of total
stroke (OR: 0.63; 95% CI: 0.43e0.92) [16].
In the present study, plasma EPA-DHA was unrelated to
total stroke incidence, which is in agreement with the
MRFIT study [16] and with a Swedish nested caseecontrol
study with 169 cases of incident stroke and 738 matched
controls [18]. Although results were not statistically
significant and confidence intervals were wide, weobserved a borderline significant positive association of
plasma EPA-DHA with ischemic stroke, but not with
hemorrhagic stroke. Also in the Swedish study [18],
a borderline positive association of EPA-DHA in erythrocytes
was found with ischemic stroke, but only in men, not in
women. Based on these results it is not possible to draw
a conclusion on the association between plasma EPA-DHA
and stroke incidence.
Fish intake in the Netherlands is low. In the full cohort,
40% of the population consumed fish less than once per
month, 8.5% never consumed fish, and 30% consumed fish at
least once a week [30]. This means that the contrast in fish
consumption in our study was small. Despite the low fish
intake, we observed correlation coefficients of w0.4 for
EPA and DHA in cholesteryl esters vs. intake data (n Z 457
participants of the MORGEN study; unpublished results)
which seemed reasonable compared to other validation
studies [31].
N-3 PUFA levels are low in cholesteryl esters. Therefore,
the variation between persons may have been small
compared to the within-subject variability. An American
validation study reported that short and long-term reli-
ability coefficients i.e. the ratio of between-person vari-
ance to total variance were >0.7 for cholesteryl ester
linoleic acid, whereas these coefficients ranged between
0.4 and 0.5 for fatty acids that composed <1% of total
cholesteryl ester fatty acids. The method variability was
only <5% of the total variability [32]. A low between to
within person variation ratio will hamper finding significant
associations between these fatty acids and stroke inci-
dence, although inverse associations of cholesteryl ester
alpha-linolenic acid with stroke [16] and EPA-DHA with CHD
[33] have been reported previously.
In conclusion, the present study did not find significant
associations of plasma n-6 or n-3 fatty acids with incident
stroke or stroke subtypes. The number of prospective
studies on biomarkers of fatty acid intake and stroke is
limited and those available are rather small. Therefore,
more and larger prospective studies are needed to establish
the relationship between PUFA status and stroke risk.Funding
Dr. Geleijnse obtained an unrestricted grant from the Alpro
Foundation, Belgium, to cover the costs of fatty acid
measurements and data analysis for the present study. The
other authors report no financial disclosures. The Moni-
toring Project on Risk Factors for Chronic Diseases
(MORGEN) study was financially supported by the Ministry of
Health, Welfare and Sport of the Netherlands, the National
Institute for Public Health and the Environment, Bilthoven,
The Netherlands, and the Europe Against Cancer Program of
the European Union. The funders had no role in study
design, data collection, analysis, and interpretation, deci-
sion to publish, or preparation of the manuscript.Disclosures
None.
742 J. De Goede et al.Author contributions
J.G., J.M.G., and D.K. designed the study; J.M.A.B. and
W.M.M.V. provided the data and critically reviewed the
manuscript; J.G. analyzed the data and performed statis-
tical analyses; J.G. drafted the paper; J.G., J.M.G., and
D.K. had primary responsibility for final content. All authors
read and approved the final version of the manuscript.
Acknowledgments
The authors would like to thank the logistics managers,
data managers, and the epidemiologists and field workers
of the Municipal Health Services in Amsterdam, Doetin-
chem, and Maastricht for their important contribution to
the data collection for this study. We are grateful to
Statistics Netherlands for the provision of causes of death
and the National Hospital Discharge Register for hospital
discharge diagnoses. The project steering committee of the
MORGEN-Study consisted of dr. H.B. Bueno de Mesquita,
prof. H.A. Smit, dr. W.M.M. Verschuren, and prof. J.C.
Seidell (project director). We kindly thank G. Doornbos and
prof. H. Boshuizen for advice on design and statistics, R.J.
de Klein and dr. J. van der Laan for assistance with sample
logistics, P Hulshof for advice on fatty acid measurements,
and B. van der Struijs and R. Hovenier for performing fatty
acid analyses. We are grateful to B. Janssen, L. Okma, B.
van der Struijs, A.M.J. Teitsma-Jansen, L.D.M. Verberne, E.
Vijge, P.E. Visser, and E. Waterham, for assistance with
sample collection.
References
[1] Murray CJL, Lopez AD. In: Murray CJL, Lopez AD, editors.
Global burden of disease 2004 update. Geneva: World Health
Organization; 2008.
[2] Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke
epidemiology: a review of population-based studies of inci-
dence, prevalence, and case-fatality in the late 20th century.
Lancet Neurol 2003;2(1):43e53.
[3] Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT,
Chaturvedi S, et al. Guidelines for the primary prevention of
stroke: a guideline for healthcare professionals from the
American Heart Association/American Stroke Association.
Stroke 2011;42(2):517e84.
[4] Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S,
Franch HA, et al. Diet and lifestyle recommendations revision
2006: a scientific statement from the American Heart Associ-
ation Nutrition Committee. Circulation 2006;114(1):82e96.
[5] Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM,
Kupelnick B, et al. n-3 Fatty acids from fish or fish-oil
supplements, but not alpha-linolenic acid, benefit cardiovas-
cular disease outcomes in primary- and secondary-prevention
studies: a systematic review. Am J Clin Nutr 2006;84(1):5e17.
[6] Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K,
Fishell V, et al. Polyunsaturated fatty acids in the food chain
in the United States. Am J Clin Nutr 2000;71(1 Suppl):
179Se88S.
[7] Zhou L, Nilsson A. Sources of eicosanoid precursor fatty acid
pools in tissues. J Lipid Res 2001;42(10):1521e42.
[8] Calder PC. n-3 Fatty acids and cardiovascular disease:
evidence explained and mechanisms explored. Clin Sci (Lond)
2004;107(1):1e11.[9] Burdge GC. Metabolism of alpha-linolenic acid in humans.
Prostaglandins Leukot Essent Fatty Acids 2006;75(3):161e8.
[10] Baylin A, Campos H. The use of fatty acid biomarkers to
reflect dietary intake. Curr Opin Lipidol 2006;17(1):22e7.
[11] Fekete K, Marosvolgyi T, Jakobik V, Decsi T. Methods of
assessment of n-3 long-chain polyunsaturated fatty acid status
in humans: a systematic review. Am J Clin Nutr 2009;89(6):
2070Se84S.
[12] Willett W. Issues in analysis and presentation of dietary data.
In: Willett WC, editor. Nutritional epidemiology. New York:
Oxford University Press, Inc.; 1998. p. 321e46.
[13] Arab L. Biomarkers of fat and fatty acid intake. J Nutr 2003;
133(Suppl. 3):925Se32S.
[14] Zock PL, Mensink RP, Harryvan J, de Vries JH, Katan MB. Fatty
acids in serum cholesteryl esters as quantitative biomarkers of
dietary intake in humans. Am J Epidemiol 1997;145(12):
1114e22.
[15] Katan MB, Deslypere JP, van Birgelen AP, Penders M,
Zegwaard M. Kinetics of the incorporation of dietary fatty
acids into serum cholesteryl esters, erythrocyte membranes,
and adipose tissue: an 18-month controlled study. J Lipid Res
1997;38(10):2012e22.
[16] Simon JA, Fong J, Bernert Jr JT, Browner WS. Serum fatty
acids and the risk of stroke. Stroke 1995;26(5):778e82.
[17] Iso H, Sato S, Umemura U, Kudo M, Koike K, Kitamura A, et al.
Linoleic acid, other fatty acids, and the risk of stroke. Stroke
2002;33(8):2086e93.
[18] Wennberg M, Bergdahl IA, Stegmayr B, Hallmans G, Lundh T,
Skerfving S, et al. Fish intake, mercury, long-chain n-3 poly-
unsaturated fatty acids and risk of stroke in northern Sweden.
Br J Nutr 2007;98(5):1038e45.
[19] Verschuren WMM, Van Leer EM, Blokstra A. Cardiovascular
disease risk factors in the Netherlands. Neth J Cardiol 1993;4:
205e10.
[20] Houterman S, Verschuren WM, Oomen CM, Boersma-
Cobbaert CM, Kromhout D. Trends in total and high density
lipoprotein cholesterol and their determinants in The
Netherlands between 1993 and 1997. Int J Epidemiol 2001;
30(5):1063e70.
[21] De Bruin A, De Bruin EI, Gast A, Kardaun JWPF, van Sijl M,
Verweij GCG. Linking data of national ambulant register and
GBA data: methods, results and quality research (in Dutch).
Koppeling van LMR- en GBA gegevens: methode, resultaten en
kwaliteitsonderzoek. The Netherlands: Statistics Netherlands:
Voorburg/Heerlen; 2003.
[22] Richardson DB. An incidence density sampling program for
nested case-control analyses. OEM 2004;61(12). e59-6e.
[23] Lubin JH, Gail MH. Biased selection of controls for case-
control analyses of cohort studies. Biometrics 1984;40(1):
63e75.
[24] Glatz JF, Soffers AE, Katan MB. Fatty acid composition of
serum cholesteryl esters and erythrocyte membranes as
indicators of linoleic acid intake in man. Am J Clin Nutr 1989;
49(2):269e76.
[25] Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort
profile: the Doetinchem cohort study. Int J Epidemiol 2008;
37(6):1236e41.
[26] Ocke´ MC, Bueno-de-Mesquita HB, Goddijn HE, Jansen A,
Pols MA, van Staveren WA, et al. The Dutch EPIC food
frequency questionnaire. I. Description of the questionnaire,
and relative validity and reproducibility for food groups. Int J
Epidemiol 1997;26(Suppl. 1):S37e48.
[27] Ocke´ MC, Bueno-de-Mesquita HB, Pols MA, Smit HA, van
Staveren WA, Kromhout D. The Dutch EPIC food frequency
questionnaire. II. Relative validity and reproducibility for
nutrients. Int J Epidemiol 1997;26(Suppl. 1):S49e58.
[28] Rothman KJ, Greenland S. Case control studies. In: Modern
epidemiology. Philadelphia: Lippincott; 1998.
N-6 and n-3 PUFA status and incident stroke 743[29] Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH.
Long-term fatty acid stability in human serum cholesteryl
ester, triglyceride, and phospholipid fractions. J Lipid Res
2010;51(9):2826e32.
[30] de Goede J, Geleijnse JM, Boer JM, Kromhout D,
Verschuren WM. Marine (n-3) fatty acids, fish consumption,
and the 10-year risk of fatal and nonfatal coronary heart
disease in a large population of Dutch adults with low fish
intake. J Nutr 2010;140(5):1023e8.
[31] Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of
adipose tissue and blood in humans and its use asa biomarker of dietary intake. Prog Lipid Res 2008;47(5):
348e80.
[32] Ma J, Folsom AR, Eckfeldt JH, Lewis L, Chambless LE. Short-
and long-term repeatability of fatty acid composition of
human plasma phospholipids and cholesterol esters. The
Atherosclerosis Risk in Communities (ARIC) Study Investiga-
tors. Am J Clin Nutr 1995;62(3):572e8.
[33] Erkkila AT, Lehto S, Pyorala K, Uusitupa MI. n-3 Fatty acids and
5-y risks of death and cardiovascular disease events in
patients with coronary artery disease. Am J Clin Nutr 2003;
78(1):65e71.
